Irene W. Althaus
Centre for Cancer Biology(AU)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, HIV/AIDS drug development and treatment, HIV Research and Treatment, Lung Cancer Treatments and Mutations, DNA and Nucleic Acid Chemistry
Most-Cited Works
- → PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib(2007)717 cited
- → Overlapping Roles and Collective Requirement for the Coreceptors GAS1, CDO, and BOC in SHH Pathway Function(2011)289 cited
- → Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor(2008)221 cited
- → Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.(1993)164 cited
- → The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase(1993)162 cited
- → Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E(1993)159 cited
- → U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication(1993)143 cited
- → Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazinemonomethanesulfonate (U-90152S), a second-generation clinical candidate(1993)123 cited
- → Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors(2006)79 cited
- → The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase(1996)74 cited